Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VIA Pharmaceuticals has started patient dosing in an ascending single-dose Phase I clinical trial to investigate VIA-3196 as a treatment for dyslipidemia novel thyroid hormone receptor beta agonist targets LDL cholesterol.
Subscribe to our email newsletter
The Phase I clinical trial of VIA-3196 will assess the safety, pharmacokinetics and pharmacodynamics of VIA-3196 in healthy subjects.
The company expects to recruit around 72 patients in the trial which is being conducted by Cetero Research at its clinical study site in Fargo, ND.
In preclinical studies, VIA-3196 has demonstrated reduction in non-HDL cholesterol, triglycerides, and fatty liver, and synergistic activity when used with statins.
VIA Pharma Research & Development senior vice president Rebecca Taub said by targeting a distinct mechanism of lipid metabolism, VIA-3196 has the potential to address hypercholesterolemia and other dyslipidemias when given alone or in combination with other lipid lowering agents.